Liraglutide
GLP-1 / metabolic · By Preptide Pro editorial team · Last updated
Liraglutide is a glp-1 / metabolic peptide, and it has an FDA-approved product. A once-daily GLP-1 receptor agonist. Approved by the FDA for type 2 diabetes and chronic weight management.
FDA-approved (see products)Chemistry (PubChem)
| PubChem CID | 16134956 |
|---|---|
| CAS number | 204656-20-2 |
| Molecular formula | C172H265N43O51 |
| Molecular weight | 3751 g/mol |
| Other names | Liraglutide, victoza, Liraglutida, NN2211, Liraglutidum, Saxenda, NN-2211, Liraglutide recombinant |
Is Liraglutide FDA-approved?
| Brand | Application | Status | Sponsor |
|---|---|---|---|
| VICTOZA | NDA022341 | Prescription | NOVO NORDISK INC |
| SAXENDA | NDA206321 | Prescription | NOVO |
How much research is there on Liraglutide?
PubMed lists 6,027 records for “liraglutide”, of which 633 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Engineering 3'-UTR hairpin structures to modulate mRNA stability and recombinant protein production in Escherichia coli. | Protein Expr Purif | 2027 Jan |
| ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations. | Spectrochim Acta A Mol Biomol Spectrosc | 2026 Dec 15 |
| Effects of sitagliptin combined with GTS-21 on improving glycemic control and diabetic nephropathy by anti-apoptosis in Lepr(db/db) mice. | Eur J Pharmacol | 2026 Dec 10 |
| Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran. | J Diabetes Metab Disord | 2026 Dec |
| Real-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes. | Metabol Open | 2026 Dec |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.